Lead program approved for Phase II
Ten drug candidates across the neural and vascular axes, advancing from a foundation of safety.
Redefining drug discovery with AI.
Future PharmaTech focuses on the two great axes of life — neural and vascular. Through its proprietary Future-AI selection platform and multi-target candidate-assessment design, the company systematically screens and optimizes candidates early in development. Ten programs now span the neural and vascular fields; lead product FPT-001 has obtained Phase II clinical approval in Australia and completed a Taiwan licensing agreement with a local pharmaceutical partner — demonstrating end-to-end momentum from AI-driven selection to clinical execution.
10
Active programs
3
Clinical regions
Phase II
Lead product stage
All programs listed are at various stages of research and development; the scientific information presented is preliminary, and no marketing authorization has been obtained in any country.
Vascular Axis
6Erectile dysfunction
PBF Pharma
Erectile dysfunction (ED)
Benign prostatic hyperplasia
MOU in progress
Benign prostatic hyperplasia (BPH)
Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH)
Coronary artery disease
Coronary artery disease (CAD)
Metabolic-associated steatohepatitis
MOU in progress
Metabolic-associated steatohepatitis (MASH)
Androgenetic Alopecia
Androgenetic Alopecia (AGA)
Neural Axis
4Vascular Dementia
MOU in progress
Vascular Dementia
Traumatic brain injury
Traumatic brain injury (TBI)
Alzheimer's disease
Alzheimer's disease (AD)
Myopia
In talks
Myopia
Progress bars represent six clinical milestones (Discovery through Phase III), colored distinctly from the homepage for easy comparison.
Patents
Future PharmaTech holds patent filings across 10 major pharmaceutical markets worldwide.
- Taiwan
- United States
- United Kingdom
- European Union
- China
- South Korea
- Japan
- Singapore
- Australia
- New Zealand